Mobile

An Open-Label, Multi-Center, Phase 2 Safety and Efficacy Study of Denosumab (AMG 162) in Subjects with Recurrent or Unresectable Giant Cell Tumor (GCT) of Bone

Mise à jour : Il y a 4 ans
Référence : EUCTR2006-006964-48

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

Primary Objectives: To evaluate response to treatment of denosumab in subjects with recurrent or unresectable GCT. Response is defined as: • elimination of giant cells, or doubling of the percentage of apoptotic giant cells, relative to baseline; or, • lack of progression of the largest lesion at week 25 by radiographic measurements

Critère d'inclusion

  • Giant Cell Tumor (GCT) of bone

Liens